[Antiproliferative effects of LY294002 on MCL Jeko-1 cell line and its mechanism]

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma.
• The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway plays a crucial role in cell proliferation and survival, making it a target for cancer therapy.
• LY294002 is a well-characterized inhibitor of PI3K.

Purpose of the Study:

• To investigate the effects of LY294002 on the proliferation and apoptosis of the MCL Jeko-1 cell line.
• To elucidate the underlying mechanism of LY294002's action on Jeko-1 cells, focusing on the PI3K/Akt signaling pathway.

Main Methods:

• MTT assay was used to determine the proliferation inhibitory rate of Jeko-1 cells treated with varying doses of LY294002.
• Flow cytometry was employed to detect the apoptosis level in Jeko-1 cells.
• Western blot analysis was performed to assess the expression levels of apoptosis-related proteins (Cyclin D1, Bcl-2, procaspase-3) and PI3K/Akt pathway proteins (p-Akt, p-mTOR, p-P70S6K).

Main Results:

• LY294002 significantly inhibited Jeko-1 cell proliferation in a dose-dependent manner.
• Apoptosis rates increased significantly with increasing concentrations of LY294002 (e.g., 43.61% at 20 µmol/L vs. 3.25% in control).
• LY294002 treatment led to decreased phosphorylation of PI3K/Akt pathway proteins (p-Akt, p-mTOR, p-P70S6K) and down-regulation of Cyclin D1, Bcl-2, and procaspase-3 expression.

Conclusions:

• LY294002 effectively inhibits Jeko-1 cell proliferation.
• The anti-proliferative and pro-apoptotic effects of LY294002 are mediated through the inhibition of the PI3K/Akt signaling pathway.
• Targeting the PI3K/Akt pathway with LY294002 presents a potential therapeutic strategy for MCL.